gvtcx

Tender for the Operating Lease of Biological Atomic Force Microscopy (bioAFM)

Swansea University Published 8 Mar 2021 Find a Tender

key details

Statuscancelled
Category (CPV) 38510000 +1 more
RegionWales
Procedureopen
OCIDocds-h6vhtk-029974

Award

SupplierValueDateStatus
not named · · unsuccessful

description

The Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6 million GBP project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is aimed at developing new therapeutics for the treatment of ovarian cancer.

A key output of the CEAT project is to establish a developmental pipeline for bioAFM applications in clinically acceptable in vitro and ex-vivo disease models, providing molecular, cellular and tissue level morphological, topographical and biomechanical information to support epigenomic investigations and the development of advanced therapeutics. As part of this requirement we have identified the need to loan specific bioAFM advanced technology from a reputable, commercial supplier, providing hybrid instrumentation compatible with current bioAFM facilities within SUMS

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
8 Mar 2021 Contract award notice (F03) Earlier regulations 004611-2021

more from Swansea University

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.